GLUE Monte Rosa Therapeutics, Inc.
Price Chart
Executive Summary
Monte Rosa Therapeutics granted inducement equity awards totaling 20,050 stock options and 4,400 RSUs to four new non-executive hires, with a grant-date exercise price of $19.67 per share. This is a routine hiring inducement for a clinical-stage biotech company and has no material impact on the company's financials or operations.
Actionable Insight
This is a routine inducement grant for new hires with no trading signal. Monitor for any future material pipeline updates or clinical trial results, which are the primary drivers for this clinical-stage biotech.
Key Facts
- Inducement awards granted to four newly hired non-executive employees.
- Awards include non-qualified stock options for 20,050 shares at $19.67 exercise price.
- Awards include restricted stock units for 4,400 shares.
- Options vest 25% on first anniversary and monthly thereafter over 3 years; RSUs vest 25% annually over 4 years.
- Awards granted under the 2026 Inducement Plan, outside stockholder-approved plans.
- Approved by compensation committee of independent directors per Nasdaq Listing Rule 5635(c)(4).
Financial Impact
Equity awards of 20,050 options and 4,400 RSUs, valued at approximately $481,000 based on $19.67 closing price. Immaterial relative to $1.7B market cap.
Risk Factors
- No material financial or operational risk from this filing.
- Clinical-stage biotech risk remains: pipeline setbacks could significantly impact stock price.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305574 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $17.59 $17.36 | ▼ −1.31% | ▼ −1.71% | $18.24 (+3.67%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $17.59 $17.36 | ▼ −1.31% | ▼ −1.71% | $18.24 (+3.67%) |
|
Jun 1, 2026
13d ago
|
Insider Cluster
| $17.74 $17.59 | ▼ −0.85% | ▼ −0.15% | $18.24 (+2.79%) |
|
May 7, 2026
5w ago
|
8-K
| $19.81 $19.39 | ▼ −2.12% | ▼ −2.95% | $18.24 (−7.95%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $19.81 $20.89 | ▲ +5.45% | ▲ +6.11% | $18.24 (−7.95%) |
|
Apr 9, 2026
9w ago
|
Insider Cluster
| $18.05 $17.48 | ▼ −3.16% | ▼ −3.10% | $18.24 (+1.02%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $16.03 $15.76 | ▼ −1.68% | ▼ −0.29% | $18.24 (+13.76%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $16.35 $16.03 | ▼ −1.96% | ▼ −2.23% | $18.24 (+11.53%) |
|
Mar 2, 2026
15w ago
|
Insider Cluster
| $18.50 $17.96 | ▼ −2.92% | ▼ −2.00% | $18.24 (−1.43%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $18.50 $17.96 | ▼ −2.92% | ▼ −2.00% | $18.24 (−1.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access